A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020 by Sai-Hong Ignatius Ou, MD PhD, Misako Nagasaka, MD

Subjects: “…ROS1 fusion partner…”
Get full text

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients by Mehta A, Saifi M, Batra U, Suryavanshi M, Gupta K

Subjects: Get full text

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors by Sudarshan R Iyer, Kevin Nusser, Kristen Jones, Pushkar Shinde, Clare Keddy, Catherine Z Beach, Erin Aguero, Jeremy Force, Ujwal Shinde, Monika A Davare

Subjects: Get full text

ROS1 positive non-small cell lung cancer with pulmonary embolism in a 22-year woman by Ananda Datta, Satya Padmaja Mantha, Suvradeep Mitra, Prasanta Mohapatra, M Srikanth Goud, Manoj Kumar Panigrahi

Subjects: “…ROS1…”
Get full text

Detection of ROS1 gene fusions using next-generation sequencing for patients with malignancy in China by Ning Li, Zhiqin Chen, Mei Huang, Ding Zhang, Mengna Hu, Feng Jiao, Ming Quan

Subjects: Get full text

Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib by Long Xu, Xiaoxia Chen, Hong Huo, Yongye Liu, Xiaodan Yang, Dejian Gu, Mingming Yuan, Min Zhang, Min Zhang, Rongrong Chen, Jiayin Wang, Zhendong Zheng

Subjects: Get full text

Histiocyte‐rich ROS1‐rearranged inflammatory myofibroblastic tumour of the trachea: A rare neoplasm presenting with asthma‐like symptoms by Chin Tong Kwok, Jason Cheuk Ho Tsang, Mary Lam, Sandy Sze Ki Ho, Chi Sum Yuen, Yiu Cheong Yeung

Subjects: Get full text

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib by Shuguang Xu, Wenxian Wang, Chunwei Xu, Xingliang Li, Junhui Ye, Youcai Zhu, Ting Ge

Subjects: Get full text

Use of crizotinib as neoadjuvant therapy for non‐small cell lung cancers patient with ROS1 rearrangement: A case report by Shikang Zhao, Shuai Zhu, Xi Lei, Dongbo Xu, Tao Shi, Qiusong Chen, Fan Ren, Gang Chen, Dingzhi Huang, Song Xu

Subjects: Get full text

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements by Yohei Takumi, Sachiko Arai, Chiaki Suzuki, Koji Fukuda, Akihiro Nishiyama, Shinji Takeuchi, Hiroki Sato, Kunio Matsumoto, Kenji Sugio, Seiji Yano

Subjects: Get full text

Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression by Tara L. Peters, Nan Chen, Logan C. Tyler, Anh T. Le, Anastasios Dimou, Robert C. Doebele

Subjects: Get full text

ROS1 in non-small-cell lung carcinoma: A narrative review by Shrinidhi Nathany, Ullas Batra, Rashi Sachdeva, Mansi Sharma, B P Amrith, Shriya Vaidya

Subjects: Get full text

Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas by Federica Riccardo, Giuseppina Barutello, Angela Petito, Lidia Tarone, Laura Conti, Maddalena Arigoni, Chiara Musiu, Stefania Izzo, Marco Volante, Dario Livio Longo, Irene Fiore Merighi, Mauro Papotti, Federica Cavallo, Elena Quaglino

Subjects: Get full text

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma by Pacenta HL, Macy ME

Subjects: Get full text

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF by Xibin Zhuang, Chao Zhao, Jiayu Li, Chunxia Su, Xiaoxia Chen, Shengxiang Ren, Xuefei Li, Caicun Zhou

Subjects: Get full text

Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment by Xugang Zhang, Baoming Wang, Chunyang Wang, Chengde Liao, Shiping Wang, Ran Cao, Tonghui Ma, Kun Wang

Subjects: “…ROS1…”
Get full text

Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH? by Lorenza Pecciarini, Emanuela Brunetto, Greta Grassini, Valeria De Pascali, Francesca Rita Ogliari, Anna Talarico, Giovanna Marra, Gilda Magliacane, Miriam Redegalli, Gianluigi Arrigoni, Chiara Lazzari, Vanesa Gregorc, Alessandra Bulotta, Claudio Doglioni, Maria Giulia Cangi

Subjects: Get full text

MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC by Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Liming Bao, Timothy R. Wilson, David Chen, Brian Simmons, Kristen M. Turner, Dean Perusse, Shailaja Kasibhatla, Jason Christiansen, Arkadiusz Z. Dudek, Robert C. Doebele

Subjects: Get full text

Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC by Yi-Long Wu, MD, Shun Lu, MD, PhD, James Chih-Hsin Yang, MD, PhD, Jianying Zhou, MD, Takashi Seto, MD, Myung-Ju Ahn, MD, PhD, Wu-Chou Su, MD, Noboru Yamamoto, MD, PhD, Dong-Wan Kim, MD, PhD, Jolanda Paolini, MSc, Tiziana Usari, BSc, Laura Iadeluca, PhD, Keith D. Wilner, PhD, Koichi Goto, MD, PhD

Subjects: Get full text

The association of ROS1 mutation with cancer immunity and its impact on the efficacy of pan-cancer immunotherapy by Yingying Li, Hong Zhao, Jinyuan Huang, Huimeng Yan, Bin Zhao

Subjects: “…ROS1…”
Get full text